Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
İçerik Proactive Investors tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Proactive Investors veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
Player FM - Podcast Uygulaması
Player FM uygulamasıyla çevrimdışı Player FM !
Player FM uygulamasıyla çevrimdışı Player FM !
hVIVO successfully completes pilot characterisation study for hMPV, prepares for challenge trials
Manage episode 460884580 series 2891889
İçerik Proactive Investors tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Proactive Investors veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
hVIVO PLC (AIM:HVO) chief scientific officer Dr Andrew Catchpole talked with Proactive's Stephen Gunnion about the company’s recent success in developing a human challenge model for human metapneumovirus (hMPV). Catchpole highlighted the pilot characterisation study, which showed clear viral infection curves, strong symptom visibility, and ensured safety for volunteers. He explained that hMPV, a significant respiratory pathogen affecting young children and the elderly, shares similarities with influenza and RSV. With this new challenge model, hVIVO now offers a powerful tool for fast-tracking the development of vaccines and antiviral therapies for hMPV. Catchpole said: “Human challenge trials are the fastest way to get efficacy data... you just can’t do this in field trials.” Moreover, he discussed encouraging progress in hMPV vaccine research, building on RSV-related breakthroughs. The data from this study will also be presented at an upcoming RSV conference in Brazil, shedding light on immune responses and potential treatment paths. Visit Proactive’s YouTube channel for more updates, and don’t forget to like the video, subscribe, and turn on notifications to stay informed. #hVIVO #hMPV #HumanChallengeTrial #VaccineDevelopment #RespiratoryViruses #ClinicalResearch #ProactiveInvestors
…
continue reading
617 bölüm
Manage episode 460884580 series 2891889
İçerik Proactive Investors tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Proactive Investors veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
hVIVO PLC (AIM:HVO) chief scientific officer Dr Andrew Catchpole talked with Proactive's Stephen Gunnion about the company’s recent success in developing a human challenge model for human metapneumovirus (hMPV). Catchpole highlighted the pilot characterisation study, which showed clear viral infection curves, strong symptom visibility, and ensured safety for volunteers. He explained that hMPV, a significant respiratory pathogen affecting young children and the elderly, shares similarities with influenza and RSV. With this new challenge model, hVIVO now offers a powerful tool for fast-tracking the development of vaccines and antiviral therapies for hMPV. Catchpole said: “Human challenge trials are the fastest way to get efficacy data... you just can’t do this in field trials.” Moreover, he discussed encouraging progress in hMPV vaccine research, building on RSV-related breakthroughs. The data from this study will also be presented at an upcoming RSV conference in Brazil, shedding light on immune responses and potential treatment paths. Visit Proactive’s YouTube channel for more updates, and don’t forget to like the video, subscribe, and turn on notifications to stay informed. #hVIVO #hMPV #HumanChallengeTrial #VaccineDevelopment #RespiratoryViruses #ClinicalResearch #ProactiveInvestors
…
continue reading
617 bölüm
Tous les épisodes
×Player FM'e Hoş Geldiniz!
Player FM şu anda sizin için internetteki yüksek kalitedeki podcast'leri arıyor. En iyi podcast uygulaması ve Android, iPhone ve internet üzerinde çalışıyor. Aboneliklerinizi cihazlar arasında eş zamanlamak için üye olun.